← Back to headlines
Unicycive Aims to Differentiate OLC in Hyperphosphatemia Market
Unicycive is working to distinguish its drug OLC within the competitive chronic kidney disease (CKD) hyperphosphatemia market.
22 Jun, 13:56 — 22 Jun, 13:56
Sources
Showing 1 of 1 sources
